Clinical trial
To Validate That Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa is a Specific Pathological Feature of Autoimmune Gastritis
NCT05238181 is registered in ClinicalTrials.gov with National Cheng-Kung University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- To Validate That Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa is a Specific Pathological Feature of Autoimmune Gastritis
- Lead sponsor
- National Cheng-Kung University Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- January 1, 2022
- Completion date
- December 31, 2024
- Enrollment
- 300 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anemia, pernicious, autoimmune diseases, gastritis, atrophic, helicobacter pylori gastritis, metaplasia